Cost-effectiveness analysis of chemotherapy for advanced gastric cancer in China

World Journal of Gastroenterology

Volumn 14, Issue 17, 2008, Pages 2715-2722

  Chen, Xin Zu ^a   Jiang, Kun ^b   Hu, Jian Kun ^a   Zhang, Bo ^a   Gou, Hong Feng ^b   Yang, Kun ^a   Chen, Zhi Xin ^a   Chen, Jia Ping ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

5 fluorouracil; Advanced gastric cancer; Chemotherapy; Cost effectiveness; Taxanes

Indexed keywords

CAPECITABINE; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINATE CALCIUM; FOLINIC ACID; METHOTREXATE; MITOMYCIN; OXALIPLATIN; PACLITAXEL; TAXANE DERIVATIVE; UFT; ANTINEOPLASTIC AGENT; TAXOID;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CASE CONTROL STUDY; CHINA; CHINESE; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG RESPONSE; ECONOMIC ASPECT; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; STOMACH CANCER; SURVIVAL TIME; ADENOCARCINOMA; CANCER STAGING; COST BENEFIT ANALYSIS; DRUG COST; ECONOMICS; MORTALITY; PATHOLOGY; REPRODUCIBILITY; STOMACH TUMOR; SURVIVAL; TREATMENT OUTCOME;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHINA; COST-BENEFIT ANALYSIS; DRUG COSTS; FLUOROURACIL; HUMANS; NEOPLASM STAGING; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 49649093724     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.14.2715     Document Type: Article

References (28)

1. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: gastric cancer, 2007
2. Chen XM, Chen GY, Wang ZR, Zhu FS, Wang XL, Zhang X. Detection of micrometastasis of gastric carcinoma in peripheral blood circulation. World J Gastroenterol 2004; 10: 804-808
3. Hu JK, Li CM, Chen XZ, Chen ZX, Zhou ZG, Zhang B, Chen JP. The effectiveness of intravenous 5-fluorouracil-containing chemotherapy after curative resection for gastric carcinoma: A systematic review of published randomized controlled trials. J Chemother 2007; 19: 359-375
4. Rivera F, Vega-Villegas ME, Lopez-Brea MF. Chemotherapy of advanced gastric cancer. Cancer Treat Rev 2007; 33: 315-324
5. Dong YL, Li R. Cost-effectiveness analysis of three chemotherapy regimens for gastric cancer. Zhongguo Yaoxue Zazhi 1999; 34: 627-628
6. Yu LX, Lv ZC. Cost-effectiveness analysis of three chemotherapy regimens for gastric cancer. Zhongguo Yiyuan Yaoxue Zazhi 1999; 19: 552-553
7. Ding WX, Zhai ZY. Cost-effectiveness analysis of three chemotherapy regimens for gastric cancer. Zhenjiang Yixueyuan Xuebao 2000; 10: 89-90
8. Qian SS, Qin LR. Cost-effectiveness analysis of four chemotherapy regimens for advanced gastric cancer. Yaowu Liuxingxue Zazhi 2002; 11: 250-251
9. Yang L, Cui CX, Wang JW. Health economics assessment of chemotherapy for gastric cancer. Zhongguo Quanke Yixue 2004; 7: 1640-1641
10. Zhou T, Yang QL, Ling Y. Cost-effectiveness analysis of two new chemotherapeutic agent containing regimens for advanced gastric cancer. Shiyong Linchuang Yiyao Zazhi 2006; 10: 28-29
11. Liu YX, Zhang J, Chen SX, Li JW. Cost-effectiveness analysis of three chemotherapeutic schemes for advanced gastric cancer. Yaoxue Shijian Zazhi 2007; 25: 117-120
12. Yang Q, Chen DS. Cost-effectiveness analysis of three chemotherapy regimens for gastric cancer. Zhongguo Yiyuan Yaoxue Zazhi 2007; 27: 230-232
13. Liu SH, Chen QS. Predictive goal of regulation of the residents' consumer price index in China. Jing Ji Shi 2005; 10: 50-52
14. Phillips B, Ball C, Sackett D, Badenoch D, Straus S, Haynes B, Dawes M. Oxford Centre for Evidence-based Medicine Levels of Evidence (May 2001). Oxford: Centre for Evidence-Based Medicine
15. Icli F, Celik I, Aykan F, Uner A, Demirkazik A, Ozet A, Ozguroglu M, Tas F, Akbulut H, Firat D. A randomized Phase III trial of etoposide, epirubicin, and cisplatin versus 5-fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma. Turkish Oncology Group. Cancer 1998; 83: 2475-2480
16. Ajani J. Review Of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers. Cancer 2006; 107: 221-231
17. Chiesa MD, Buti S, Tomasello G, Negri F, Buononato M, Brunelli A, Lazzarelli S, Brighenti M, Donati G, Passalacqua R. A pilot phase II study of chemotherapy with oxaliplatin, folinic acid, 5-fluorouracil and irinotecan in metastatic gastric cancer. Tumori 2007; 93: 244-247
18. Nardi M, Azzarello D, Maisano R, Del Medico P, Giannicola R, Raffaele M, Zavettieri K Costarella S, Falzea A. FOLFOX-4 regimen as fist-line chemotherapy in elderly patients with advanced gastric cancer: a safety study. J Chemother 2007; 19: 85-89
19. Beretta E, Di Bartolomeo M, Buzzoni R, Ferrario E, Mariani L, Gevorgyan A, Bajetta E. Irinotecan, fluorouracil and folinic acid (FOLFIRI) as effective treatment combination for patients with advanced gastric cancer in poor clinical condition. Tumori 2006; 92: 379-383
20. Kim SG, Oh SY, Kwon HC, Lee S, Kim JH, Kim SH, Kim M. A phase II study of irinotecan with bi-weekly, low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as salvage therapy for patients with advanced or metastatic gastric cancer. Jpn J Clin Oncol 2007; 37: 744-749
21. Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Marabotti C, Van Cutsem E. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol 2007; 25: 3205-3209
22. Lokich JJ, Sonneborn H, Anderson NR, Bern MM, Coco FV, Dow E, Oliynyk P. Combined paclitaxel, cisplatin, and etoposide for patients with previously untreated esophageal and gastroesophageal carcinomas. Cancer 1999; 85: 2347-2351
23. Kim YH, Shin SW, Kim BS, Kim JH, Kim JG, Mok YJ, Kim CS, Rhyu HS, Hyun JH, Kim JS. Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma. Cancer 1999; 85: 295-301
24. Yamaguchi K, Nakagawa S, Yabusaki H, Nashimoto A. Combination chemotherapy with 5-fluorouracil, cisplatin and paclitaxel for pretreated patients with advanced gastric cancer. Anticancer Res 2007; 27: 3535-3539
25. Ninomiya M, Kondo K, Matsuo K, Hirabayashi N, Kojima H, Kobayashi M, Kawamura S, Ando T, Musha N, Konno H, Nagata N, Usuki H, Miyashita Y, Oba K, Morita S, Sakamoto J. Multicenter phase II trial of combination chemotherapy with weekly paclitaxel and 5-fluorouracil for the treatment of advanced or recurrent gastric carcinoma. J Chemother 2007; 19: 444-450
26. Kim YH, Shin SW, Kim BS, Kim JH, Kim JG, Mok YJ, Kim CS, Rhyu HS, Hyun JH, Kim JS. Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma. Cancer 1999; 85: 295-301
27. Roth AD, Ajani J. Docetaxel-based chemotherapy in the treatment of gastric cancer. Ann Oncol 2003; 14 Suppl 2: ii41-ii44
28. Ajani JA. Standard of care for gastric cancer based on meta-analysis? Treading on thin ice or it is very nice! J Clin Oncol 2006; 24: 5473-5474; author reply 5474-5476